Myriad Genetics establishes November 8th as “Heditary Breast Cancer and Ovarian Cancer (HBOC) Day” in hopes of early detection of breast cancer and other diseases Image
URL: Myriad Genetics LLC Press release: November 8, 2024 Myriad Genetics establishes November 8th as “Heditary Breast and Ovarian Cancer (HBOC) Day” in hopes of early detection of breast cancer, etc. Myriad Genetics and SRL jointly host an event
commemorating the establishment of “Heditary Breast and Ovarian Cancer (HBOC) Day”
https://prcdn.freetls.fastly.net/release_image/72624/17/72624-17-d1d291b71aaa16682421202ad2f1029f-1399×428.png
https://shiritai-hboc.jp/assets/img/hboc_logo.zip ) can be used. Image
URL: https://prcdn.freetls.fastly.net/release_image/72624/17/72624-17-400136de2c7373f6bd45c32abd27c9c2-1934×973.jpg What is hereditary breast and ovarian cancer (HBOC)? Breast cancer* is the most common cancer among Japanese women. One of the causes is “hereditary breast and ovarian cancer,” acronym HBOC ( H ereditary B reast and O varian C ancer). People with HBOC are born with genetic changes that increase their risk of developing breast cancer and ovarian cancer. HBOC, which is still relatively unknown in Japan, can be diagnosed by consulting with a specialized doctor or genetic counselor and undergoing genetic testing at a medical institution. For more information, please see the HBOC information site operated by Myriad Genetics, “I want to know the truth! Hereditary breast and ovarian cancer” ( https://shiritai-hboc.jp/ ) Please see. * Ministry of Health, Labor and Welfare “National Cancer Registry Incidence Number and Rate Report 2020” Event commemorating the establishment of “Heditary Breast and Ovarian Cancer (HBOC) Day”
https://prcdn.freetls.fastly.net/release_image/72624/17/72624-17-de0ac6db5c6b92bf00fbf75a42d7823b-974×663.jpg From left: Yosuke Kuronaka, Director of Marketing Department, Myriad Genetics LLC, Shunsuke Kuraoka, Representative, Myriad Genetics LLC, Dr. Arisa Ueki, Director, Department of Clinical Genetics, Cancer Institute Ariake Hospital, Director of Showa University Clinical Genome Research Institute/Showa University Dr. Seigo Nakamura, Director of the Hospital Breast Center, Makiko Dazai, Chairman of the Board of Directors of Clavis Arx, a specified non-profit organization, and Yasuhisa Arita, General Manager of SRL Genomics Headquarters, SRL Co., Ltd.
URL: https://prcdn.freetls.fastly.net/release_image/72624/17/72624-17-4de8a08ef0dab539b123a2aaa3ecc380-510×354.jpg An anniversary registration certificate was presented to Shunsuke Kuraoka, representative of Myriad Genetics, from Kiyoshi Kase, representative director of the Japan Anniversary Association. Kiyoshi Kase: “I believe that “Heditary Breast and Ovarian Cancer (HBOC) Day” is a meaningful anniversary that can be useful in three ways: useful to society, useful to individuals, and useful to the
future.Many people We would like to appeal in various ways to make people aware of this anniversary.”
https://prcdn.freetls.fastly.net/release_image/72624/17/72624-17-2e2bcf120173df99198ae85529c7c1b5-510×338.jpg Myriad Genetics Marketing Department Manager Yosuke Kuronaka announced the results of a survey on hereditary breast and ovarian cancer (HBOC) conducted prior to this event. This is a survey conducted on 1,000 women in their 20s to 60s across the country regarding awareness and understanding of HBOC, genetic testing, etc., and the following points were clarified. ■Breast cancer is recognized to the extent that it is a familiar disease, but awareness and understanding of HBOC is very low. ■It is not known that genetic testing and risk reduction surgery are covered by insurance. ■People with HBOC and their families are not aware that genetic counseling is available. ■Even if a blood relative is diagnosed with HBOC, less than half of the people want to undergo genetic testing. ■If you have a family member or close relative who has had cancer, you will view HBOC as something personal to you, but if you have no family member or close relative who has had cancer, you will be less interested. Watch the video here:
https://youtu.be/bJu1URvIqI0 Click here for research materials: https://shiritai-hboc.jp/assets/file/report.zip [Survey overview] Survey method: WEB questionnaire survey Survey period: October 16th (Wednesday) to 18th (Friday), 2024 Number of samples collected: 1,000 people Survey target: Women in their 20s to 60s nationwide (excluding medical and genetics-related workers)
https://prcdn.freetls.fastly.net/release_image/72624/17/72624-17-1d80d4f8d003f67feb4a66e246d7b3e3-721×356.jpg A talk session was held with experts about the actual situation and issues regarding HBOC and genetic testing that were revealed through the survey. (Moderator: Medical journalist/caster Madoka Mori) Watch the video here: https://youtu.be/rHeyHxSZeV4 Below are some of the comments made during the session. Dr. Seigo Nakamura, Director, Showa University Clinical Genome Research Institute / Director, Showa University Hospital Breast Center “Since 2014, we have been building a database on the incidence of HBOC in Japanese people. Based on this knowledge, we were able to link genetic testing and risk-reducing surgery to insurance coverage. If detected, it could help reduce the use of anticancer drugs and reduce the risk of recurrence after surgery. Although social awareness of HBOC has gradually increased, there is still the issue that insurance does not cover testing and treatment for patients’ families and others who have not developed cancer. Even though HBOC has the word “hereditary” attached to it, we never think of it specifically. For example, just as we treat diabetes and high blood pressure to prevent cerebral infarction and heart disease, we believe that recognizing changes in individual genes can lead to early detection and risk reduction of cancer. I am. To this end, I feel that we need an environment that makes it easier for people who have not developed cancer to undergo testing and medical treatment. ” Arisa Ueki, Director, Department of Clinical Genetics, Cancer Research Group Ariake Hospital “At Cancer Institute Ariake Hospital, we advocate and disseminate the concept of “Gene
Awareness” in cancer treatment. This idea is to help patients become familiar with their own genes, understand their constitution correctly, and face cancer. We believe that making your doctor aware of this will help them choose the appropriate treatment based on the genetic diagnosis. I believe that not only patients but also medical professionals have vague concerns about hereditary tumors such as HBOC. Our next role is to develop educational programs in the form of improving genetic literacy so that attending physicians, nurses, pharmacists, and others have the correct knowledge and to help them recognize the significance of working as a team in medical care. I recognize it. ” Ms. Makiko Dazai, Chairperson of Clavis Arx, a specified non-profit organization “I personally feel that I am where I am today because I underwent genetic testing and risk-reducing surgery.Nowadays, testing and treatment are covered by insurance, and in an environment where patients can access accurate information, I feel that patients are now able to choose their own treatment.The importance of undergoing genetic testing as part of treatment is becoming more and more understood not only by breast cancer patients but also by other cancer patients. I feel that. I believe that the establishment of a memorial day like this with the aim of letting more people know about HBOC will bring great hope not only to those with HBOC, but also to those with other genetic changes. . We would like to continue communicating about HBOC in cooperation with the media. ” About SRL Since its founding in 1970, SRL has maintained its corporate philosophy of “contributing to the creation of a healthy and prosperous society,” and as a member of the H.U. Group, one of Japan’s leading healthcare groups, has contributed to the development of medical care with a focus on the clinical testing business. I’m doing it. Test data provided based on an international standard quality control system plays a fundamental role in medical practice in Japan. From 2022, in order to further strengthen these systems, we have started operation of the “H.U. Bioness Complex” as a new central laboratory in Akiruno City, Tokyo. Under a comprehensive business alliance with Myriad Genetics, medical institutions in Japan submit BRCA1/2 We collect genetic test samples, transport them to the United States, and provide consultation on analysis results.
https://www.srl-group.co.jp/ About Myriad Genetics Myriad Genetics is a leading company in genetic testing and precision medicine that enriches people’s health and daily lives by providing important individual genetic information. Myriad Genetics develops and sells genetic tests that can determine the risk of developing a disease, assess the risk of disease progression, improve patient care by healthcare professionals, and reduce healthcare costs in multiple medical fields. We are making changes. https://myriadgenetics.jp/